## Catalytic Asymmetric Nucleophilic Fluorination Using BF<sub>3</sub>·Et<sub>2</sub>O as Fluorine Source and Activating Reagent

Nat. Commun. **2021**, *12*, 3957; DOI: 10.1038/s41467-021-24278-3

With the growing applications of fluorinated compounds in modern organic chemistry, pharmaceutical sciences, agrochemistry and materials chemistry, the development of innovative strategies for achieving the selective fluorination of organic molecules represents one of the most hectic areas in chemical research.<sup>1,2</sup> In particular, the construction of stereogenic C-F bond-substituted centers is a critically important, albeit still challenging, task in fluorine chemistry.3 Professor Xianxing Jiang from Sun Yat-sen University (P. R. of China), who is strongly interested in organofluorine chemistry, reckons that asymmetric fluorinations using nucleophilic fluorine sources are much less developed as compared to electrophilic strategies, due to the unique features of fluorine atoms (such as high oxidation potential, high hydration energy).1 "In current research, the main nucleophilic fluorine sources applied in asymmetric fluorinations are PhCOF, pyridine · HF, Et<sub>3</sub>N · HF and metal fluorides," he noted, adding: "Despite elegant works reported in the literature, several practical disadvantages discouraged further large-scale utilization of these compounds for nucleophilic fluorinations: for example, the high toxicity and biohazardous nature of HF-bases, and the poor solubility of metal fluorides in organic solvents, coupled with limited strategies to control their reactivity, are among the main reasons."4

According to Professor Jiang, compared to metal catalysts, chiral hypervalent iodine catalysts have recently attracted much attention in organic synthesis due to their excellent pro-

perties, such as mild reaction conditions, ease of preparation, the ability to dispense with complex ligands, and being metal-free. Importantly, Jacobsen and co-workers reported the viability of catalytic asymmetric nucleophilic fluorinations using a chiral iodine catalyst and pyridine  $\cdot$  HF in the presence of m-CPBA, he noted.

Professor Jiang and his research group have been interested in hypervalent iodine catalyzed/promoted reactions (such as asymmetric halogenations, oxidative cyclization and oxyaminations) and Lewis acid catalyzed/mediated chemical synthesis. Professor Jiang explained: "The initial phase of our research was focused on catalytic asymmetric nucleophilic fluorinations using the 'chiral iodine catalyst + pyridine·HF' catalytic system, inspired by Jacobsen's work. We found that  $BF_3 \cdot Et_2O$ , which is a versatile and cheap Lewis acid, could also be applied as fluorine source in some fluorinations. We thought that if we could combine the hypervalent chiral iodine catalyst and  $BF_3 \cdot Et_2O$  together, we could then apply the 'combination' to reactions with appropriate substrates to form chiral fluorinated products. If so, it would be a welcome and significant step in fluorine chemistry."

Professor Jiang continued: "Firstly, we applied the combination of hypervalent iodine compound and  $BF_3 \cdot Et_2O$  to reactions with the amide 1a in DCM at 0 °C (Scheme 1). To our delight, the fluorinated products 1b could be generated through the catalytic process. On the basis of this experimental result, we then used chiral iodine reagents instead of iodobenzene

Scheme 1 Catalyst screening

Synform Literature Coverage

(IB) to carry out the reaction. At first, the chiral iodine(III) reagent  ${\bf 2a}$  was applied to catalyze the fluorinations, affording the desired product with 37% ee (major diastereomer). Next, we examined spirobiindane chiral iodine catalysts  ${\bf 2b}$  and  ${\bf 2c}$  which gave the desired products with higher ee and dr values. Axisymmetric chiral iodine catalysts were then examined to improve the stereoselectivity of the fluorinated product. Catalyst screening indicated that  ${\bf 2d}$  was the best choice (Scheme 1). After several initial trials aimed at studying the effect of different experimental factors such as solvents, reaction temperature, concentration, we set out to optimize the model catalytic asymmetric aminofluorination of  ${\bf 1a}$  in the presence of 15 mol% of ligand loading, using  ${\bf BF}_3 \cdot {\bf Et}_2 {\bf O}$  as the fluorine reagent in DCE at  $-25\,^{\circ}{\rm C}$ . This part of the research project was carried out by Dr. Weiwei Zhu and Xiang Zhen."

To gain a better understanding of this catalytic fluorination system, the authors conducted control experiments and DFT calculations. Professor Jiang said: "It is worth noting that when PhIF<sub>2</sub>, Py·HF or Et<sub>3</sub>N·HF were used as fluorine source, **1b** could NOT be obtained. In the beginning we thought fluoride was produced from Ph-I-OBF<sub>3</sub> directly during the ca-

talytic cycle. However, DFT calculations didn't support this initial hypothesis, as it was found to be energetically disfavored. Then we modified the possible mechanism: the 'fluorine source' was hypothesized to be the BF<sub>4</sub><sup>-</sup> anion (generated in situ) and this turned out to be energetically possible (Scheme 2). The process would thus follow a fluorination/1,2-aryl migration/cyclization cascade.<sup>8</sup> In this scenario, BF<sub>3</sub>·Et<sub>2</sub>O plays the role of a fluorinating reagent, as well as the activating reagent for activation of iodosylbenzene."

In order to expand the applications of this catalytic fluorination system, Professor Jiang and co-workers designed and synthesized substrates **3a–I** to undergo the fluorination reaction (Scheme 3). "As expected, the fluorinated products **4a–I** could be obtained as we hoped, based on the possible catalytic cycle. Screening of different reaction parameters gave the optimal reaction conditions for the formation of fluorinated products with good to excellent ee values," remarked Professor Jiang.

Professor Jiang recalls at the onset of this novel research program, three main challenges were identified. "The first was the choice of the fluorinating reagent. As mentioned above,

Scheme 2 Mechanistic studies

**Scheme 3** Substrate scope expansion



currently the most applied fluorine sources in nucleophilic fluorinations are Py·HF, Et<sub>2</sub>N·HF or metal fluorides, which have been used in elegant works, but the practical disadvantages described earlier are detrimental in terms of large-scale utilization. Considering that BF<sub>3</sub>·Et<sub>2</sub>O could be applied in achiral fluorinations as nucleophilic fluorine source and inspired by the asymmetric fluorinations achieved with chiral iodine catalysts, we came up with the idea that the combination of 'chiral iodine catalyst and BF<sub>3</sub>·Et<sub>2</sub>O' may be an alternative for asymmetric fluorinations. The second was the design of the substrates. Based on the previous related work on fluorination reactions and the possible mechanism of hypervalent iodine catalyzed fluorination reactions, we designed and synthe sized the original substrate 1a. By the way, 1a was tested for halogenations in previous work.9-11 What inspired us to study the catalytic system further for catalytic asymmetric fluorinations was that the substrate 1a could react with the 'IB + BF<sub>3</sub>·Et<sub>2</sub>O' system in the presence of *m*-CPBA to generate fluorinated products. The third challenge was the possible competition between Lewis acid promoted cyclization reaction and catalytic fluorinations. In our previous work, we reported a Lewis acid promoted cyclization of unsaturated alkenes."12

The current catalytic system had an important influence on the group's research. In view of the advantages of using  $BF_3 \cdot Et_2O$  as fluorine source in asymmetric nucleophilic fluorinations, Professor Jiang revealed that his group will continue to focus on catalytic, asymmetric nucleophilic fluorinations using  $BF_3 \cdot Et_2O$  as fluorine source and activating reagents in their future research. Professor Jiang explained: "We aim to expand the substrate scope and synthesize more chiral fluorinated molecules using our "chiral hypervalent iodine +  $BF_3 \cdot Et_2O$ " catalytic system. In addition, asymmetric fluorinations using other nucleophilic fluorine sources are still one of our main research topics."

Professor Jiang concluded: "Fluorinated oxazine derivatives could be obtained with high stereoselectivities (up to > 20% ee and > 20:1 dr), whereas benzocycloheptane derivatives could be synthesized with high enantioselectivities (up to 85% ee) and in one step, through this metal-free and complex-ligand-free catalytic system. Oxazine derivatives are widely present in bioactive and pharmaceutical molecules, and fluorinated 1,2-amino alcohols, which are important intermediates in organic synthesis and pharmaceutical chemistry, could be obtained through hydrolysis of the products. Besides, ring-open ing polymerization of the N,O-heterocycles can be applied to prepare functional materials. We believe that this process provides not only a direct access to fluoro-oxazine/benzoxaze-pine skeletons, but also a foundation for further development of new types of asymmetric nucleophilic fluorinations in

future applications. Studies on the applicability of this asymmetric fluorination methodology using other substrates are presently ongoing in our group."



## **REFERENCES**

- (1) P. A. Champagne, J. Desroches, J.-D. Hamel, M. Vandamme, J.-F. Paquin *Chem. Rev.* **2015**, *115*, 9073–9174.
- (2) Y. Zhu, J. Han, J. Wang, N. Shibata, M. Sodeoka, V. A. Soloshonok, J. A. S. Coelho, F. D. Toste *Chem. Rev.* **2018**, *118*, 3887–3964.
- (3) J. A. Ma, D. Cahard Chem. Rev. **2004**, 104, 6119–6146.
- (4) W. Zhu, X. Zhen, J. Wu, Y. Cheng, J. An, X. Ma, J. Liu, Y. Qin, H. Zhu, J. Xue, X. Jiang *Nat. Commun.* **2021**, *12*, 3957.
- (5) A. Yoshimura, V. V. Zhdankin *Chem. Rev.* **2016**, *116*, 3328–3435.
- (6) T. Wirth Angew. Chem. Int. Ed. 2005, 44, 3656–3665.
- (7) S. M. Banik, J. W. Medley, E. N. Jacobsen *Science* **2016**, 353, 51–54.
- (8) A. Ulmer, C. Brunner, A. M. Arnold, A. Pöthig, T. Gulder *Chem. Eur. J.* **2016**, *22*, 3660–3664.
- (9) Y. Kawato, A. Kubota, H. Ono, H. Egami, Y. Hamashima *Org. Lett.* **2015**, *17*, 1244–1247.
- (10) Y. Nagao, T. Hisanaga, H. Egami, Y. Kawato, Y. Hamashima *Chem. Eur. J.* **2017**, *2*3, 16758–16762.
- (11) G.-Q. Liu, C.-H. Yang, Y.-M. Li *J. Org. Chem.* **2015**, *80*, 11339–11350.
- (12) J. An, J. Liu, Y. Shi, W. Zhu, G. Guo, X. Jiang, J. Xue, H. Zhang *Curr. Org. Chem.* **2020**, *24*, 1263–1273.

A186

Jing-Yuan Wu received her B.S. from

Shangdong University (P. R. of China)

in 2018. Subsequently, she began her

M.S. studies under the supervision of

Prof. Xian-Xing Jiang and Prof. Xiao-

Oing Cai at Sun Yet-Sen University (P.

R. of China). Her research interests

focus on covalent antibodies and

**Ya-Ping Cheng** received her B.S. from

Northwest Agriculture & Forest University (P. R. of China) in 2018. Sub-

sequently, she began her M.S. studies

under the supervision of Prof. Xiao-

Qing Cai and Prof. Xian-Xing Jiang at

Sun Yet-sen University (P. R. of China).

Her research interests focus on coval-

ent antibodies and organic synthesis.

organic synthesis.

## About the authors



Prof. X. X. Jiang

Xian-xing Jiang received his Ph.D. in organic chemistry from Lanzhou University (P. R. of China) in 2011 under the direction of Prof. Rui Wang. He was a postdoctoral researcher under the supervision of Prof. Carlos F. Barbas III at The Scripps Research Institute (USA) from 2012 to 2014. Dr. Jiang became a full professor at the School of Pharmaceutical Sciences at Sun Yat-Sen University (P. R. of China) in 2014. His research interests focus on asymmetric synthesis, chemical biology and peptide drugs.



Dr. W. W. Zhu



X. Zhen

Wei-wei Zhu received his B.S. (2013) and M.S. (2016) degrees from the College of Chemistry and Chemical Engineering, Lanzhou University (P. R. of China). He earned his Ph.D. from the School of Pharmaceutical Sciences, Sun Yat-Sen University (P. R. of China) in 2020 under the supervision of Prof. X. X. Jiang. He is now a postdoctoral researcher at the laboratory of Prof. Huihao Zhou. His current research interests include asymmetric synthesis and functional materials synthesis.

Xiang Zhen received his B.S. from Southwest University of Science and Technology (P. R. of China) in 2016 and M.S. from Lanzhou University (P. R. of China). Subsequently, he began his Ph.D. studies under the supervision of Prof. Chunan Fan at Lanzhou University (P. R. of China). His research interests focus on asymmetric synthesis methodology.



J. Y. Wu





**Jun-Kai An** received his B.S. from Beijing Institute of Technology (P. R. of China) in 2017. Subsequently, he began M.S. studies under the supervision of Prof. Ji-Jun Xue at Lanzhou University (P. R. of China). His research interests focus on medicinal chemistry and fluorine chemistry.



J. K. An



X. Y. Ma

**Xing-Yu Ma** received his M.S from Zhengzhou University (P. R. of China) in 2015. Subsequently, he began his Ph.D. studies under the supervision of Prof. Xian-Xing Jiang at Sun Yat-Sen University (P. R. of China). His research interests focus on biomedicine and asymmetric synthesis.

>>

Synform Literature Coverage



Yu-Ji Qin received his B.S. from Huazhong University of Science and Technology (P. R. of China) in 2020. Subsequently, he began his M.S. studies under the supervision of Prof. Xian-Xing Jiang at Sun Yat-Sen University (P. R. of China). His research interests focus on organocatalysis and fluorine chemistry.



Dr. H. Zhu

Y. J. Qin

J. K. Liu



Lanzhou University (P. R. of China) under the supervision of Prof. Rui Wang in 2018. His research interests focus on asymmetric synthesis and fluorine chemistry.

Ji-Kun Liu received his M.S. from



Dr. J. J. Xue

**Hao Zhu** is currently an associate professor at Lanzhou University (P. R. of China). He received his B.S. and Ph.D. degrees from Lanzhou University in 2004 and 2013, respectively. His research interests focus on the design and development of functional materials, air pollution control, sewage treatment and environmental monitoring.

the State Key Laboratory of Applied Organic Chemistry, Lanzhou University (P. R. of China). He obtained his Ph.D. at Lanzhou University (P. R. of China). His current research interests focus on organic synthesis methodology and medicinal chemistry.

Jijun Xue is an associate professor at